TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16641947
Drug: Neurocognitive tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurocognitive tests administered (11 tests resulting in 24 individual scores)
Study: 11399983
Drug: Amprenavir (APV)
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amprenavir (APV) 450 mg with Ritonavir (RTV) 300 mg
Study: 11399983
Drug: Amprenavir (APV)
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amprenavir (APV) 450 mg with Ritonavir (RTV) 100 mg
Study: 11399983
Drug: Amprenavir (APV)
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amprenavir (APV) 900 mg with Ritonavir (RTV) 100 mg
Study: 11399983
Drug: Ritonavir (RTV)
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir (RTV) co-administration with APV
Study: 11399983
Drug: Ritonavir (RTV)
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir (RTV) 300 mg
Study: 11399983
Drug: Ritonavir (RTV)
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir (RTV) 100 mg
Study: 9757514
Drug: Hop-valerian preparation
Normalized name: HOPS
DrugBank: Hops (DB10687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hop-valerian preparation
Study: 9757514
Drug: Benzodiazepine preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine preparation
Study: 7914050
Drug: Haloperidol (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2, 4 and 6 mg)
Study: 7914050
Drug: Remoxipride (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remoxipride (100 and 150 mg)
Study: 16989189
Drug: 633-nm and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 633-nm and 830-nm LED treatments
Study: 15259281
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day of tricalcium phosphate (TCP)
Study: 15259281
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day of ossein‐hydroxyapatite (OHC)
Study: 8570762
Drug: Brofaromine (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brofaromine (selective and reversible inhibitor of monoamine oxidase type A)
Study: 8570762
Drug: Imipramine (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (standard tricyclic compound)
Study: 105442
Drug: Chemotherapeutic agents
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapeutic agents
Study: 29354921
Drug: Scraping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scraping therapy (4 sessions over 4 weeks)
Study: 29354921
Drug: Scraping therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scraping therapy (lung qi deficiency and cold group)
Study: 29354921
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg, once a day for 4 weeks)
Study: 23598607
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment for 6 months
Study: 25601933
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment (per-protocol analysis)
Study: 20711439
Drug: Superficial heat
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Superficial heat therapy
Study: 17394940
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 45 mg orally three times daily
Study: 16287453
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg daily for 2 weeks
Study: 28333362
Drug: Budesonide multimatrix
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide multimatrix 9 mg
Study: 26600646
Drug: Structured Oral
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Oral Examination (SOE)
Study: 23924446
Drug: Immediate intravesical
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate intravesical instillation of Pirarubicin (THP) 30 mg/50 ml within 24 hours post TUR, followed by regular instillations once a week for 8 weeks, then once a month for 1 year.
Study: 23924446
Drug: Regular intravesical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular intravesical therapy only.
Study: 23924446
Drug: Regular intravesical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular intravesical therapy only for low and intermediate-risk patients.
Study: 23924446
Drug: Regular intravesical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular intravesical therapy only for high-risk patients.
Study: 19589565
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg followed by 200 mg every 12 hours for 10 days
Study: 11385230
Drug: Griseofulvin 600
Normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Griseofulvin 600 mg twice daily for 12 months
Study: 11385230
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg daily for 4 months
Study: 11385230
Drug: Itraconazole pulse
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole pulse therapy (200 mg twice daily for 1 week with 3 weeks off between pulses)
Study: 1392793
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg daily for 12 weeks
Study: 11385230
Drug: Fluconazole 150
Normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 150 mg daily for 12 weeks
Study: 1443356
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g intramuscular (i.m.) 1 hour preoperatively and a second dose 1 hour before catheter removal (Study 1)
Study: 1443356
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g i.m. 1 hour preoperatively (Study 2)
Study: 1443356
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g i.m. 1 hour before catheter removal (Study 2)
Study: 15724865
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no magnesium therapy)
Study: 6399346
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium therapy (subgroup without heart failure)
Study: 29532734
Drug: sirukumab 50
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirukumab 50 mg q4w
Study: 29532734
Drug: sirukumab 100
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirukumab 100 mg q2w
Study: 22773291
Drug: Physiotherapy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy group (PG) - 15 minutes of daily passive movements with gentle joint compression 5 days a week
Study: 19965548
Drug: Cinacalcet plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet plus low-dose calcitriol analogs (Cinacalcet-D)
Study: 18664988
Drug: Penicillin/erythromycin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin/erythromycin therapy at school for positive throat cultures
Study: 15882245
Drug: Moxifloxacin, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin, amoxicillin, and esomeprazole (Group MAE)
Study: 15882245
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy with clarithromycin, amoxicillin, and esomeprazole (Group CAE)
Study: 15882245
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy with tinidazole (Group CTE)
Study: 12963604
Drug: Topical 0.3%
Normalized name: triclosan topical 0.3% topical bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.3% ciprofloxacin solution or ointment
Study: 15321076
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg subarachnoid diamorphine
Study: 15321076
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg epidural diamorphine
Study: 8675360
Drug: Random urine
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random urine urea excretion indices
Study: 3893776
Drug: Chloroquine single
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine single dose of 10 mg/kg
Study: 3893776
Drug: Chloroquine full
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine full dose of 25 mg/kg
Study: 29777297
Drug: High verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High verapamil administration (18%)
Study: 27119576
Drug: LCZ696 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 (400 mg, single dose) with omeprazole (40 mg q.d.)
Study: 27119576
Drug: LCZ696 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 (400 mg, single dose) with metformin (1000 mg q.d.)
Study: 27119576
Drug: LCZ696 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 (400 mg, single dose) with levonorgestrel-ethinyl estradiol (150/30 μg single dose)
Study: 18094224
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg alone
Study: 18094224
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg followed by aspirin 325 mg 2 hours later
Study: 18094224
Drug: Aspirin with
Normalized name: Bayer Aspirin with Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin with NSAID (ibuprofen or naproxen)
Study: 1596968
Drug: 0.5 ml.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml.kg‐1 bupivacaine 0.125% with 1:200,000 epinephrine
Study: 1596968
Drug: 1 ml.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml.kg‐1 bupivacaine 0.125% with 1:200,000 epinephrine
Study: 31248843
Drug: Triple-drug group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug group (cyclosporine, mycophenolate mofetil, and sirolimus)
Study: 31248843
Drug: Triple-drug group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug group
Study: 29102441
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 2 injections
Study: 24996030
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DSP and SG with ALB
Study: 20473067
Drug: Antidepressant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant therapy alone (Control)
Study: 15231010
Drug: Oral daily
Normalized name: Summer's Eve Sheer Floral Daily Cloths
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral daily ibandronate (2.5 mg)
Study: 11874442
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg sibutramine bid
Study: 11874442
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg orlistat tid
Study: 11874442
Drug: 850 mg
Normalized name: bran 850 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 850 mg metformin bid
Study: 10440605
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg or 10 mg)
Study: 7560246
Drug: MS-CRS (controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: MS-CRS (controlled-release suppository)
Study: 6938013
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg diethylstilbestrol (DES) daily by mouth
Study: 31134731
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT-T) delivered by trainee psychologists
Study: 28880609
Drug: Discontinued use
Normalized name: Entex HC Discontinued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued use of antipsychotics
Study: 28880609
Drug: Continued use
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued use of antipsychotics
Study: 19249182
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg infused over 1 h every 8 h for complicated intra-abdominal infections
Study: 19249182
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg infused over 4 h every 8 h for hospital-acquired pneumonia
Study: 12957743
Drug: Metronidazole 750
Normalized name: metronidazole 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 750 mg daily in divided doses for 14 days
Study: 16962882
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg dapoxetine
Study: 16962882
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg dapoxetine
Study: 29313486
Drug: Ivermectin (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (0.15 mg/kg)
Study: 21197713
Drug: Valganciclovir (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir (900 mg) once daily for up to 200 days
Study: 21197713
Drug: Valganciclovir (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir (900 mg) once daily for up to 100 days
Study: 18438718
Drug: ACEI/ARB discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI/ARB discontinuation group
Study: 14982549
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of antiretroviral medication
Study: 14982549
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of drugs or alcohol in the previous 30 days
Study: 11314834
Drug: Pethidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 0.5 mg/kg
Study: 9388088
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (3766 J [900 calories], 50 g of fat)
Study: 9388088
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (3766 J [900 calories], 0 g of fat)
Study: 9388088
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal with vitamins C (1 g) and E (800 IU)
Study: 9388088
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal with vitamins C (1 g) and E (800 IU)
Study: 3147423
Drug: Lignocaine injections
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine injections
Study: 28038497
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral instructions (Control)
Study: 26705931
Drug: High-Dose Trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose Trivalent Inactivated Influenza Vaccine (60 μg HA/strain/dose)
Study: 26705931
Drug: Standard-Dose Trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-Dose Trivalent Inactivated Influenza Vaccine (15 μg HA/strain/dose)
Study: 19515542
Drug: Dipeptidyl Peptidase‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipeptidyl Peptidase‐4 (DPP‐4) inhibitors
Study: 19515542
Drug: DPP‐4 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPP‐4 inhibitors
Study: 10645918
Drug: Abciximab plus
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab plus reduced-dose tPA (combination therapy)
Study: 8785148
Drug: Vecuronium 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.05 mg kg‐1
Study: 1558994
Drug: Topical alpha-interferon
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical alpha-interferon ointment with dimethyl sulfoxide
Study: 28864073
Drug: Intensity-modulated radiotherapy
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity-modulated radiotherapy (IMRT) planned using pre-induction chemotherapy images (group A)
Study: 28864073
Drug: Intensity-modulated radiotherapy
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity-modulated radiotherapy (IMRT) planned using post-induction chemotherapy images (group B)
Study: 26967222
Drug: SR 23
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 23 mg/day donepezil
Study: 26967222
Drug: IR 10
Normalized name: Oralair 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR 10 mg/day donepezil
Study: 22849758
Drug: Progesterone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (300 mg at h.s. daily)
Study: 24347664
Drug: Defibrillator-only therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrillator-only therapy
Study: 15179643
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (Dysport) injections (200U each into medial and lateral heads of gastrocnemius and 400U each into tibialis posterior) and Functional Electric Stimulation (FES) used daily for 16 weeks
Study: 11453318
Drug: Almitrine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (50 mg bid)
Study: 11453318
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (20 mg tid)
Study: 11453318
Drug: Almitrine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (50 mg bid) and Medroxyprogesterone acetate (20 mg tid)
Study: 9870483
Drug: Bicarbonate solution
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate solution (38 mmol/l of bicarbonate)
Study: 9870483
Drug: Bicarbonate/lactate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate/lactate solution (25 mmol/l bicarbonate and 15 mmol/l lactate)
Study: 9870483
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution (40 mmol/l lactate)
Study: 1358607
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg three times daily
Study: 27235677
Drug: 20‐mL 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20‐mL 1% buffered lidocaine four‐site PCB with a 3‐min wait prior to cervical dilation
Study: 27235677
Drug: 20‐mL 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20‐mL 1% buffered lidocaine four‐site PCB with no wait prior to cervical dilation
Study: 27235677
Drug: 20‐mL 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20‐mL 1% buffered lidocaine four‐site PCB (four‐site)
Study: 27235677
Drug: 20‐mL 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20‐mL 1% buffered lidocaine two‐site PCB
Study: 18356335
Drug: Sodium iron
Normalized name: Sodium iron EDTA
DrugBank: Sodium feredetate (DB13381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium iron EDTA (NaFeEDTA) at 10 mg/kg flour
Study: 18356335
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous fumarate at 20 mg/kg flour
Study: 18356335
Drug: Electrolytic iron
Normalized name: electrolytic iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrolytic iron at 35 mg/kg flour
Study: 8035590
Drug: Pseudoephedrine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine (60 mg)
Study: 7614644
Drug: Granisetron plus
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron plus Dexamethasone (20 micrograms.kg‐1 and 8 mg)
Study: 7211827
Drug: Control centers
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control centers (CC)
Study: 25026508
Drug: Breathing retraining
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing retraining plus manual therapy (MT), n=30
Study: 25026508
Drug: Breathing retraining
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breathing retraining (standard treatment), n=30
Study: 17570848
Drug: Artemether plus
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether plus lumefantrine (Coartem; four doses)
Study: 17570848
Drug: Artemether plus
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether plus lumefantrine (Coartem; six doses)
Study: 11820045
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide gel with 3% potassium nitrate and 0.11 fluoride ion
Study: 11820045
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide gel only (control)
Study: 9924466
Drug: 150 IU
Normalized name: Follitropin Beta 150 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU oral nHuIFN-alpha/day
Study: 3041248
Drug: Hormone treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone treatment (oestrogen and norethisterone acetate)
Study: 23652778
Drug: Furosemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20 mg intravenous injection)
Study: 17627814
Drug: Oral DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral DHEA (50mg capsules, 2 capsules daily for 14 days)
Study: 17627814
Drug: Percutaneous DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous DHEA (4g of 10% DHEA cream or gel daily for 14 days)
Study: 11748599
Drug: Eye Movement
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Movement Desensitization and Reprocessing (EMDR) treatment
Study: 9449495
Drug: Aerosol beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol beclomethasone dipropionate spray (84 microg four times per day)
Study: 9449495
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (doses adjusted for optimum control, twice per day)